Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

May 15, 2026 5:03 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found